GLP-1s for PCOS

The short answer

GLP-1 medications are not FDA-approved for PCOS, but they are increasingly used off-label and the mechanistic case is strong. By improving insulin sensitivity, lowering weight, and reducing androgen excess that follows from hyperinsulinemia, semaglutide and tirzepatide can meaningfully improve PCOS symptoms — including menstrual regularity, ovulation, and metabolic markers — in many patients. They are not a fertility drug, and they are contraindicated in pregnancy, so timing matters.

What the research shows

PCOS is driven, in roughly 70% of patients, by underlying insulin resistance. Excess insulin stimulates the ovaries to overproduce androgens, which disrupts the LH/FSH ratio and prevents normal follicle development. The metabolic loop — insulin resistance, weight gain, more insulin resistance — is what most PCOS treatment is actually targeting, whether the label says so or not. Metformin has been the workhorse for decades. GLP-1 receptor agonists hit the same axis more potently.

The clinical evidence in PCOS specifically is still building but consistent. Multiple small randomized trials and meta-analyses — most using liraglutide or semaglutide — have shown that GLP-1 therapy in women with PCOS produces greater weight loss than metformin, larger reductions in HbA1c and fasting insulin, lower free testosterone, and improved menstrual regularity. A 2024 meta-analysis of GLP-1s in PCOS reported clinically meaningful improvements in BMI, insulin resistance (HOMA-IR), and hyperandrogenism markers compared to standard care. The biggest signal is in the metabolic phenotype.

The larger obesity trials are also relevant by extension. STEP 1 (semaglutide 2.4 mg) produced roughly 15% mean weight loss over 68 weeks in adults with overweight/obesity. SURMOUNT-1 (tirzepatide) produced roughly 20% at the high dose. In PCOS, even 5–10% weight loss is enough to restore ovulation in a large fraction of patients, so the absolute weight-loss magnitude these drugs deliver is well above the threshold where reproductive function tends to come back.

Ovulation and fertility are where it gets nuanced. GLP-1s improve the metabolic environment that disrupts ovulation, and pregnancies on therapy are documented — but the drugs themselves carry a recommendation to stop at least two months before attempting pregnancy because of unknown effects on the developing fetus. If pregnancy is the immediate goal, GLP-1s are best framed as a pre-conception metabolic optimization tool, not a fertility treatment.

How it tends to work in practice

The patients who respond most dramatically are those with the metabolic PCOS phenotype — higher BMI, elevated fasting insulin, classic dark velvety skin patches (acanthosis nigricans), strong hunger and food noise. These are the patients where the underlying driver is insulin resistance, and the GLP-1 mechanism aligns most directly with the problem. Menstrual regularity often improves within a few months as weight comes down and insulin levels normalize.

Lean PCOS is a different story. Roughly 20–30% of PCOS patients have a normal or low BMI, and their androgen excess is less obviously insulin-driven. GLP-1s in this group are less well-studied and the risk-benefit calculation is different — meaningful weight loss may not be desired, and the side-effect burden may not be worth it for the smaller metabolic gain. Many specialists prefer to start with inositol, metformin, or hormonal management in lean PCOS.

What patients tend to notice in the first few months: appetite drops sharply, especially for the carb-and-sugar drive that PCOS hunger often resembles; energy improves as glucose stabilizes; periods become more regular within 3–6 months for many; acne and hirsutism (excess hair growth) respond more slowly, often over 9–12 months, because androgen-driven follicles take time to reset. The reproductive improvements lag the metabolic ones.

Common questions

Keep exploring

Browse all GLP-1 guides.